2023 World Conference on Lung Cancer (Posters)-EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina

EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the progression-free survival (PFS) of patients with EGFR mutant non-small cell lung cancer (NSCLC) who were treated with the drug osimertinib. Osimertinib is an irreversible epidermal growth factor receptor tyrosine kinase inhibitor specifically used in patients with advanced NSCLC with EGFR activating mutations. The study aimed to compare the effect of specific exon mutations and co-existing programmed death ligand (PDL) mutations on PFS in patients treated with osimertinib.<br /><br />The retrospective observational study analyzed patients in South Carolina between 2012-2023. Out of a total population of 3523 patients with NSCLC, 47 patients with EGFR mutations were identified. Of these, 37 patients were treated with osimertinib. The patients were assessed for PFS based on specific exon mutations.<br /><br />The results showed that patients with the exon 21 L858R mutation had a median PFS of 22 months on osimertinib. Patients with exon 19 deletion mutation had a PFS of 13 months, while patients with exon 20 insertion mutations had a PFS of 3 months. There was no statistically significant difference in PFS outcomes between exon 19 deletion and exon 21 L858R mutated NSCLC.<br /><br />However, patients with exon 20 mutations had a statistically significant decrease in PFS compared to all other studied mutations, suggesting the need for a different treatment approach for these patients. Additionally, 11 patients with a co-existing PDL mutation and EGFR mutation were identified. Their PFS on osimertinib was found to be 6 months.<br /><br />In conclusion, while there was no significant difference in PFS between exon 19 deletion and exon 21 L858R mutation NSCLC patients treated with osimertinib, there was a significant decrease in PFS for patients with exon 20 mutations. The study highlights the need for further research on co-existing PDL mutations with EGFR and their associated treatment outcomes.

Asset Subtitle

Michael Pavy

Meta Tag

Speaker Michael Pavy

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

progression-free survival

EGFR mutant non-small cell lung cancer

osimertinib

epidermal growth factor receptor tyrosine kinase inhibitor

NSCLC

EGFR activating mutations

exon mutations

programmed death ligand mutations

retrospective observational study

South Carolina